JP2013510883A5 - - Google Patents

Download PDF

Info

Publication number
JP2013510883A5
JP2013510883A5 JP2012539063A JP2012539063A JP2013510883A5 JP 2013510883 A5 JP2013510883 A5 JP 2013510883A5 JP 2012539063 A JP2012539063 A JP 2012539063A JP 2012539063 A JP2012539063 A JP 2012539063A JP 2013510883 A5 JP2013510883 A5 JP 2013510883A5
Authority
JP
Japan
Prior art keywords
compound
alkyl
moiety
formula
membered saturated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012539063A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013510883A (ja
JP5988379B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/056757 external-priority patent/WO2011060389A1/en
Publication of JP2013510883A publication Critical patent/JP2013510883A/ja
Publication of JP2013510883A5 publication Critical patent/JP2013510883A5/ja
Application granted granted Critical
Publication of JP5988379B2 publication Critical patent/JP5988379B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012539063A 2009-11-13 2010-11-15 スフィンゴシン−1−リン酸受容体変調因子および不斉合成方法 Active JP5988379B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26128209P 2009-11-13 2009-11-13
US61/261,282 2009-11-13
US26247409P 2009-11-18 2009-11-18
US61/262,474 2009-11-18
PCT/US2010/056757 WO2011060389A1 (en) 2009-11-13 2010-11-15 Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis

Publications (3)

Publication Number Publication Date
JP2013510883A JP2013510883A (ja) 2013-03-28
JP2013510883A5 true JP2013510883A5 (Direct) 2014-01-09
JP5988379B2 JP5988379B2 (ja) 2016-09-07

Family

ID=43992104

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012539063A Active JP5988379B2 (ja) 2009-11-13 2010-11-15 スフィンゴシン−1−リン酸受容体変調因子および不斉合成方法

Country Status (25)

Country Link
US (3) US8357706B2 (Direct)
EP (1) EP2498611B1 (Direct)
JP (1) JP5988379B2 (Direct)
KR (1) KR101781233B1 (Direct)
CN (1) CN102724880B (Direct)
AU (1) AU2010320041B2 (Direct)
BR (1) BR112012011430A8 (Direct)
CA (1) CA2780433C (Direct)
CY (1) CY1120427T1 (Direct)
DK (1) DK2498611T3 (Direct)
EA (1) EA023183B1 (Direct)
ES (1) ES2665461T3 (Direct)
HR (1) HRP20180527T1 (Direct)
HU (1) HUE036391T2 (Direct)
IL (1) IL219690B (Direct)
LT (1) LT2498611T (Direct)
MX (1) MX2012005562A (Direct)
MY (1) MY160907A (Direct)
NZ (1) NZ599913A (Direct)
PH (1) PH12012500938A1 (Direct)
PL (1) PL2498611T3 (Direct)
PT (1) PT2498611T (Direct)
RS (1) RS57070B1 (Direct)
SI (1) SI2498611T1 (Direct)
WO (1) WO2011060389A1 (Direct)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201800288T1 (it) * 2009-11-13 2018-07-17 Celgene Int Ii Sarl Modulatori selettivi del recettore della sfingosina 1 fosfato e metodi di sintesi chirale
MY160907A (en) * 2009-11-13 2017-03-31 Receptos Inc Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
US9481659B2 (en) 2011-05-13 2016-11-01 Celgene International Ii Sàrl Selective heterocyclic sphingosine 1 phosphate receptor modulators
CN103251950B (zh) * 2012-02-16 2018-10-02 中国人民解放军军事科学院军事医学研究院辐射医学研究所 S1p受体调节剂防治肠型放射病及放射性肠炎的用途
KR20150083864A (ko) * 2012-11-16 2015-07-20 에프. 호프만-라 로슈 아게 2-트리플루오로메틸 이소니코틴산 및 에스터의 제조 공정
HUE039931T2 (hu) 2013-02-20 2019-02-28 Lg Chemical Ltd Szfingozin-1-foszfát receptor agonisták, azok elkészítési eljárásai, és azokat aktív ágensként tartalmazó gyógyszerészeti készítmények
EP3062792A1 (en) * 2013-11-01 2016-09-07 Celgene International II Sarl Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith
HUE060594T2 (hu) 2015-11-13 2023-03-28 Oppilan Pharma Ltd Heterociklusos vegyületek betegség kezelésére
CA3009428A1 (en) * 2015-12-22 2017-06-29 AbbVie Deutschland GmbH & Co. KG Fused (hetero)cyclic compounds as s1p modulators
EP3448519A4 (en) * 2016-04-29 2020-01-22 Board Of Regents, The University Of Texas System SIGMA RECEPTOR BINDING
CN109661391B (zh) * 2016-07-22 2022-04-19 南京明德新药研发有限公司 S1p1激动剂及其应用
CN106749213B (zh) * 2016-11-25 2019-07-02 济南大学 一种具有1,2,4-恶二唑结构的吲哚衍生物及制备方法和在制备抗菌药物中的应用
CN108727292A (zh) * 2017-04-21 2018-11-02 宁波爱诺医药科技有限公司 一种奥扎莫德及其中间体的制备方法
CN108727291A (zh) * 2017-04-21 2018-11-02 宁波爱诺医药科技有限公司 奥扎莫德及其中间体的制备方法
AR116479A1 (es) 2018-09-25 2021-05-12 Quim Sintetica S A Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios
CN110256288A (zh) * 2019-05-13 2019-09-20 苏州山青竹生物医药有限公司 一种制备(s)-1-氨基-2,3-二氢-1h-茚-4-甲腈的方法
CN112062785B (zh) * 2019-06-11 2023-06-27 广东东阳光药业有限公司 奥扎莫德及其中间体的制备方法
MX2022008342A (es) * 2020-01-06 2022-08-04 Arena Pharm Inc Metodos para tratar afecciones relacionadas con el receptor de s1p1.
ES3034261T3 (en) 2020-02-06 2025-08-14 Mitsubishi Tanabe Pharma Corp Amiselimod for use in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome
US20230124301A1 (en) * 2020-03-04 2023-04-20 Helioeast Pharmaceutical Co., Ltd. Tricyclic compounds and use thereof
CN121194965A (zh) 2023-05-31 2025-12-23 奎米卡新特缇卡股份有限公司 盐酸奥扎莫德的无定形形式和晶型

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479544A (en) 1974-02-07 1977-07-13 American Cyanamid Co 1,2,3,4-tetrahydro-1-naphthylurea derivatives their preparation and their use
FR2628103B1 (fr) 1988-03-03 1991-06-14 Roussel Uclaf Nouveaux esters pyrethrinoides portant un noyau indanyle, leur procede de preparation et leur application comme pesticides
US5039802A (en) 1990-04-18 1991-08-13 Merck & Co., Inc. Arylation process for preparation of chiral catalysts for ketone reduction
WO1992018462A1 (en) * 1991-04-12 1992-10-29 Schering Corporation Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase
GB2290790A (en) * 1994-06-30 1996-01-10 Merck & Co Inc Asymmetric synthesis of 6-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
AU741924B2 (en) 1998-01-23 2001-12-13 Sankyo Company Limited Spiropiperidine derivatives
US20040058894A1 (en) 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists
WO2004058149A2 (en) * 2002-12-20 2004-07-15 Merck & Co., Inc. 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles
ES2926542T3 (es) * 2003-04-11 2022-10-26 Ptc Therapeutics Inc Compuestos de ácido 1,2,4-oxadiazol benzoico y su uso para supresión de mutaciones finalizadoras y el tratamiento de enfermedades
JP2007528872A (ja) * 2003-10-01 2007-10-18 メルク エンド カムパニー インコーポレーテッド S1p受容体アゴニストとしての3,5−アリール置換、ヘテロアリール置換またはシクロアルキル置換された1,2,4−オキサジアゾール化合物
CA2547198A1 (en) 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
US7585881B2 (en) 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US20060173183A1 (en) 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
WO2006120577A1 (en) 2005-02-22 2006-11-16 Teva Pharmaceutical Industries Ltd. Improved process for the synthesis of enantiomeric indanylamine derivatives
KR100667075B1 (ko) 2005-07-22 2007-01-10 삼성에스디아이 주식회사 주사 구동부 및 이를 포함하는 유기 전계발광 표시장치
WO2007071045A1 (en) 2005-12-21 2007-06-28 Joseph Gabriele Catecholamine regulated protein
US20090163482A1 (en) 2006-03-13 2009-06-25 Mchardy Stanton Furst Tetralines antagonists of the h-3 receptor
US20080009534A1 (en) 2006-07-07 2008-01-10 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
NZ577111A (en) * 2006-12-15 2012-05-25 Abbott Lab Novel oxadiazole compounds
WO2008143729A2 (en) 2007-02-28 2008-11-27 Rib-X Pharmaceuticals, Inc. Macrolide compounds and methods of making and using the same
US20090298894A1 (en) 2008-04-21 2009-12-03 Asahi Kasei Pharma Corporation Amino acid compounds
PL2291080T3 (pl) 2008-05-14 2015-12-31 Scripps Research Inst Nowe modulatory receptorów sfingozyno-1-fosforanu
WO2011005290A1 (en) 2009-06-23 2011-01-13 Arena Pharmaceuticals, Inc. Disubstituted oxadiazole derivatives useful in the treatment of autoimmune and inflammatory disorders
MY160907A (en) 2009-11-13 2017-03-31 Receptos Inc Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
SMT201800288T1 (it) 2009-11-13 2018-07-17 Celgene Int Ii Sarl Modulatori selettivi del recettore della sfingosina 1 fosfato e metodi di sintesi chirale
CA2780641C (en) 2009-11-13 2019-03-05 Receptos, Inc. Selective heterocyclic sphingosine 1 phosphate receptor modulators
EA201490748A1 (ru) 2011-10-12 2014-12-30 Тева Фармасьютикал Индастриз Лтд. Лечение рассеянного склероза комбинацией лахинимода и финголимода

Similar Documents

Publication Publication Date Title
JP2013510883A5 (Direct)
JP2013510884A5 (Direct)
JP2014511892A5 (Direct)
JP2018515495A5 (Direct)
JP2009543860A5 (Direct)
JP2019520416A5 (Direct)
JP2014520809A5 (Direct)
JP6261011B2 (ja) 眼疾患処置薬
JP2011523412A5 (Direct)
RU2010143857A (ru) Тетрагидрофенантридиноны и тетрагидроциклопентахинолиноны в качестве ингибриторов parp и ингибиторов полимеризации тубулина
JP2019501133A5 (Direct)
JP2010524932A5 (Direct)
JP2020507589A5 (Direct)
CA2672373A1 (en) Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
JP2015505296A5 (Direct)
JP2011509309A5 (Direct)
JP2016503009A5 (Direct)
JP2013542267A5 (Direct)
JP2009538910A5 (Direct)
JP2011509301A5 (Direct)
CA2679198A1 (en) Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
JP2010527984A5 (Direct)
JP2007505931A5 (Direct)
JP2014517836A5 (Direct)
JP2011517697A5 (Direct)